Basic research aiming at the application of SCGB3A2 for chronic obstructive pulmonary disease therapeutic drug.

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K09208
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Respiratory organ internal medicine
• Research Institution: Yamagata University
• Principal Investigator: Kurotani Reiko 山形大学, 大学院理工学研究科, 准教授 (00453043)
• Co-Investigator(Kenkyū-buntansha): 阿部 宏之 山形大学, 大学院理工学研究科, 教授 (10375199) ; 今野 博行 山形大学, 大学院理工学研究科, 准教授 (50325247) ; 柴田 陽光 山形大学, 医学部, 講師 (60333978)
• Co-Investigator(Renkei-kenkyūsha): KUMAKI Nobue 東海大学, 医学部, 講師 (90366021)
• Research Collaborator: ONO Sotaro ; KINOSHITA Takamune
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: SCGB3A2 / COPD / 肺気腫 / STAT / A1AT

Outline of Final Research Achievements

In this study, we aimed at basic research aiming at application of secretoglobin (SCGB) 3A2 to chronic obstructive pulmonary disease (COPD) treatment. COPD is a lung disease considered to be one of lifestyle-related diseases caused by long-term smoking, and shows features such as thickening, stenosis of the peripheral airway wall and destruction of the alveolar wall. SCGB3A2 has an anti-inflammatory effect, an improvement effect of pulmonary fibrosis, and a growth promoting effect in lung development. Therefore, we expected that SCGB 3 A 2 will also have an effective effect on COPD. Mainly, the improvement effect of SCGB3A2 on COPD was examined using COPD mouse model prepared using Scgb3a2 gene modified mouse. In addition, we clarified the COPD improvement mechanism in the cell culture system. This study suggested that SCGB3A2 upregulates the expression of alpha 1 antitrypsin by phosphorylation of STAT3, and SCGB3A2 showed an effect of improving pulmonary emphysema, in particular.

Free Research Field

細胞生物学，分子生物学